The Farnesoid-x-receptor (FXR) and the G-protein coupled bile acid receptor 1 (GPBAR1), two bile acid activated receptors, have been investigated for their potential in treating NASH. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatohepatitis.